InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.
Currently, this type of approved mesh technology is exclusively used by InspireMD in its unique and patent pending MGuard(TM) mesh protected coronary stent system. "We are satisfied that the InspireMD mission and technology to improve the outcome of PCI in AMI, was acknowledged by the ESC. In the light of the extremely positive experience gathered with MGuard we are much honored that the ESC acknowledges the MGuard mesh technology for thrombotic lesions. The outcome from our clinical studies in Acute MI as well as SVG patients is very positive and we are very encouraged by this recognition of the European Society of MGuard" stated Ofir Paz, InspireMD's CEO.
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare